Sulfhydryl blocker-induced rat colonic inflammation is ameliorated by inhibition of nitric oxide synthase
References (27)
- et al.
Peroxynitrite-induced rat colitis: a new model of colonic inflammation
Gastroenterology
(1993) - et al.
Role of prostaglandins in ulcerative colitis: enhanced production during active disease and inhibition by sulphasalazine
Gastroenterology
(1978) - et al.
Nitric oxide synthase from cerebellum catalyzes the formation of equimolar quantities of nitric oxide and citrulline from l-arginine
Biochem Biophys Res Commun
(1992) - et al.
Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker
J Invest Dermatol
(1982) - et al.
Inflammatory mediators of experimental colitis in rats
Gastroenterology
(1989) - et al.
A comparative analysis of two models of colitis in rats
Gastroenterology
(1992) - et al.
Widespread tissue distribution, species distribution and changes in activity of Ca2+-dependent and Ca2+-independent nitric oxide synthases
Febs Lett
(1991) - et al.
Mucosal injury and inflammation in a model of chronic granulomatous colitis in rats
Gastroenterology
(1993) - et al.
Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene
Cell
(1993) - et al.
Glutathione
Annu Rev Biochem
(1983)
Glutathione modulates toxic oxygen metabolite injury of canine chief cell monolayers in primary culture
Am J Physiol
Reduced glutathione modulates Ca2+-mediated damage to rabbit isolated gastric mucosal cells
Am J Physiol
Sulphydryl blockers induce severe inflammatory gastritis in rats
Gastroenterology
Cited by (64)
Identification of cysteinyl-leukotriene-receptor 1 antagonists as ligands for the bile acid receptor GPBAR1
2020, Biochemical PharmacologyCitation Excerpt :Classical studies in these models and IBD patients have shown that development of colon inflammation in these settings associates with enhanced mucosal formation of LTB4 and CysLTs [55–59], while an enhanced urinary excretion of LTE4, correlating with the severity of inflammation, has been reported in ulcerative colitis patients [60]. Despite the fact that LTs and CysLTs are positive regulators of leukocyte trafficking in inflamed tissues, other reports have shown less clear cut results and that efficacy of clinically available CysLT1R antagonists in treating inflammation in rodent model of colitis is controversial [57–59]. Indeed, while the 5-Lox inhibitor zileuton attenuates inflammation in models of colitis and was shown moderately effective in maintaining remission in ulcerative colitis patients suffering from a mild-moderate disease [61], montelukast lacks any therapeutic effects [62].
Molecular characterization and hypoxia-induced upregulation of neuronal nitric oxide synthase in Atlantic croaker: Reversal by antioxidant and estrogen treatments
2015, Comparative Biochemistry and Physiology -Part A : Molecular and Integrative PhysiologyCitation Excerpt :The observation that NEM increased O2− production and nNOS expression in normoxic control fish similar to that seen in hypoxia-exposed fish is consistent with a role of nNOS in ROS generation and indicates a potential mechanism of hypoxia-induced impairment of hypothalamic functions through modification of the sulfhydryl (SH) groups in the reactive centers of enzymes. The results showing that treatment with an antioxidant prevents hypoxia-induced increases in nNOS and ROS production further supports this proposed mechanism because antioxidants have been shown to exert a protective effect on ROS-induced protein damage through SH modifications (Rachmilewitz et al., 1995). In addition, the demonstration that repeated injections with an aromatase-inhibitor increased hypothalamic O2− production and nNOS expression in normoxic control fish suggests that maintenance of the E2 status is essential for preventing upregulation of ROS and nNOS.
Inducible nitric oxide synthase involvement in the mechanism of action of Saccharomyces boulardii in castor oil-induced diarrhoea in rats
2005, Nitric Oxide - Biology and ChemistryInduction of alkaline phosphatase in the inflamed intestine: A novel pharmacological target for inflammatory bowel disease
2004, Biochemical PharmacologyCitation Excerpt :Animals were sacrificed after 1 week. Iodoacetamide colitis: halothane anesthetized rats received 0.25 ml of iodoacetamide intrarectally (6 mg) [25]. Controls received PBS.